Regulation
Freenome’s lung cancer test receives FDA breakthrough status
Freenome received FDA breakthrough device designation for SimpleScreen Lung, a blood-based test for lung cancer screening in adults. Breakthrough status expedites review of devices that address unmet medical needs and offer potential advantages over existing alternatives.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network